Results 171 to 180 of about 9,605 (202)
Some of the next articles are maybe not open access.
Seminars in Arthritis and Rheumatism, 2016
To provide an overview of the underlying scientific principles and standards for developing a biosimilar product.An Internet-based literature search through June 2015 was performed for information related to biosimilar manufacturing and development, including a review of regulatory guidelines and requirements.Biologics, both biosimilars and their ...
Ahmad, Al-Sabbagh +3 more
openaire +2 more sources
To provide an overview of the underlying scientific principles and standards for developing a biosimilar product.An Internet-based literature search through June 2015 was performed for information related to biosimilar manufacturing and development, including a review of regulatory guidelines and requirements.Biologics, both biosimilars and their ...
Ahmad, Al-Sabbagh +3 more
openaire +2 more sources
Expert Opinion on Biological Therapy, 2012
Until now most insulin used in developed countries is manufactured and distributed by a small number of multinational companies. Other pharmaceutical companies - many of these are located in countries such as India or China - are also able to manufacture insulin with modern biotechnological methods.
openaire +2 more sources
Until now most insulin used in developed countries is manufactured and distributed by a small number of multinational companies. Other pharmaceutical companies - many of these are located in countries such as India or China - are also able to manufacture insulin with modern biotechnological methods.
openaire +2 more sources
Biosimilars: Are They Bioequivalent?
Digestive Diseases, 2014Biologics have revolutionized several areas of medical therapeutics, and dozens of them are used by millions of patients. Monoclonal antibodies are only one type of biologics, but more than 900 are now in different phases of development. These drugs are complex to make and not cheap.
openaire +2 more sources
Biosimilars 101: An Introduction to Biosimilars
2018The surging costs of biological medicines worldwide have necessitated the development of biosimilars. These highly similar versions of off-patent biological products entered the EU in 2006 and the U.S. in 2015. Unlike small molecule generic drugs, which are chemically identical to their originator products, biosimilar products cannot be identical ...
openaire +1 more source
2017
Biosimilars are a new class of drugs, which are derived from live organism through the recombinant DNA technology. These are recently introduced in the pharmaceutical field for the preparation of drug to prevent or control the diseases. Patients with diabetes and renal failure may already be receiving biosimilar epoetin and may receive same insulin in ...
Anil K. Sharma +2 more
openaire +1 more source
Biosimilars are a new class of drugs, which are derived from live organism through the recombinant DNA technology. These are recently introduced in the pharmaceutical field for the preparation of drug to prevent or control the diseases. Patients with diabetes and renal failure may already be receiving biosimilar epoetin and may receive same insulin in ...
Anil K. Sharma +2 more
openaire +1 more source
Biosimilar anti-VEGF—Yardsticks to ensure biosimilarity
Eye, 2022Ashish Sharma +4 more
openaire +3 more sources
Biosimilars. Was für Arzneimittel sind Biosimilars?
2019Kurzinformation für ...
openaire +1 more source
The Disappointment of the Biosimilar
Journal of Law, Medicine & Ethics, 2018openaire +2 more sources